eflornithine has been researched along with Malignant Melanoma in 33 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present study was to investigate the effect of polyamine depletion by alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, on the growth and differentiation of B16 melanoma cells grown in culture and also as solid tumors in mice." | 7.67 | Effect of inhibition of polyamine biosynthesis by DL-alpha-difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo. ( Chang, CC; Lachmann, PJ; Prakash, NJ; Sunkara, PS, 1985) |
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 5.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| " Although the three sublines were 2- to 10-fold less sensitive than the parent line to classical MDR-type agents, they were found in dose-response studies to be significantly more sensitive to DENSPM than the parent line." | 5.29 | Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine. ( Bergeron, RJ; Ganis, B; Kramer, DL; Porter, CW; Rustum, Y; Wrzosek, C, 1994) |
| " Median effect analysis of the DFMO + IFN inhibition of C8161 cells demonstrated that the 2 agents interacted synergistically over the entire dose-response curve." | 5.27 | Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid. ( Bregman, MD; Meyskens, FL, 1986) |
| "Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, and human leukocyte interferon (IFN-alpha) have synergistic anti-tumor activities in vivo in B 16 melanoma and in vitro against several human cancer cell lines." | 3.67 | Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients. ( Benjamin, R; Gutterman, J; Kantarjian, H; Plager, C; Quesada, J; Talpaz, M, 1986) |
| "The objective of the present study was to investigate the effect of polyamine depletion by alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, on the growth and differentiation of B16 melanoma cells grown in culture and also as solid tumors in mice." | 3.67 | Effect of inhibition of polyamine biosynthesis by DL-alpha-difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo. ( Chang, CC; Lachmann, PJ; Prakash, NJ; Sunkara, PS, 1985) |
| "alpha-Difluoromethyl ornithine and mouse type 1 interferon, when administered simultaneously, were highly toxic to B16 melanoma cells in culture." | 3.66 | Tumor suppression with a combination of alpha-difluoromethyl ornithine and interferon. ( Mayer, GD; Prakash, NJ; Sjoerdsma, A; Sunkara, PS, 1983) |
| "An exposure of cultured Cloudman S91 melanoma cells to inhibitors of polyamine biosynthesis, 2-difluoromethylornithine (DFMO) and methylglyoxal bis(guanylhydrazone) (MGBG), distinctly promoted the expression of differentiated biochemical functions of the tumor cells." | 3.66 | Stimulation of melanotic expression in murine melanoma cells exposed to polyamine antimetabolites. ( Jänne, J; Käpyaho, K, 1983) |
| "The incidence of skin cancer (both melanoma and non-melanoma) continues to grow at an alarming rate." | 2.41 | The state-of-the-art in chemoprevention of skin cancer. ( Alberts, DS; Dorr, RT; Stratton, SP, 2000) |
| "Melanoma is a disease that need not be deadly." | 2.38 | The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening. ( Greene, MH, 1993) |
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 1.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| " Although the three sublines were 2- to 10-fold less sensitive than the parent line to classical MDR-type agents, they were found in dose-response studies to be significantly more sensitive to DENSPM than the parent line." | 1.29 | Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine. ( Bergeron, RJ; Ganis, B; Kramer, DL; Porter, CW; Rustum, Y; Wrzosek, C, 1994) |
| "When tilorone was given 7 days after tumor inoculation, it did not show any potentiation of antitumor activity of DFMO." | 1.27 | Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers. ( Hagan, AC; Lachmann, PJ; Mayer, GD; Prakash, NJ; Rosenberger, AL; Sunkara, PS, 1984) |
| " Median effect analysis of the DFMO + IFN inhibition of C8161 cells demonstrated that the 2 agents interacted synergistically over the entire dose-response curve." | 1.27 | Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid. ( Bregman, MD; Meyskens, FL, 1986) |
| "The in vivo growth of ascite plasmocytoma of solid melanoma B-16 cells in mice was also effectively inhibited by DFMO." | 1.27 | [Antiproliferative activity of difluoromethylornithine and the factors decreasing its effectiveness in malignant growth]. ( Diachok, FI; Gridina, NIa; Khomenko, AK; Kudriavets, IuI; Semeniĭ, VIa, 1986) |
| " A dose-response curve was developed for each interferon in which the maximum dose applied gave at least 30% growth inhibition of control values after 96-128 h of continuous exposure." | 1.27 | The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human cell lines. ( Harvey, HA; Leitzel, KE; Lipton, A; Pegg, AE; Wolf, LM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (63.64) | 18.7374 |
| 1990's | 8 (24.24) | 18.2507 |
| 2000's | 3 (9.09) | 29.6817 |
| 2010's | 1 (3.03) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pommergaard, HC | 1 |
| Burcharth, J | 1 |
| Rosenberg, J | 1 |
| Raskov, H | 1 |
| Sunkara, PS | 8 |
| Prakash, NJ | 5 |
| Mayer, GD | 2 |
| Sjoerdsma, A | 3 |
| Käpyaho, K | 2 |
| Jänne, J | 2 |
| Schechter, PJ | 1 |
| Nishioka, K | 1 |
| Rosenberger, AL | 4 |
| Hagan, AC | 1 |
| Lachmann, PJ | 2 |
| Porter, CW | 3 |
| Ganis, B | 1 |
| Rustum, Y | 1 |
| Wrzosek, C | 1 |
| Kramer, DL | 2 |
| Bergeron, RJ | 1 |
| Greene, MH | 1 |
| Gerner, EW | 2 |
| Kurtts, TA | 1 |
| Fuller, DJ | 2 |
| Casero, RA | 1 |
| Shappell, NW | 1 |
| Fogel-Petrovic, MF | 1 |
| Stratton, SP | 1 |
| Dorr, RT | 1 |
| Alberts, DS | 1 |
| Weeks, RS | 1 |
| Vanderwerf, SM | 1 |
| Carlson, CL | 1 |
| Burns, MR | 1 |
| O'Day, CL | 1 |
| Cai, F | 1 |
| Devens, BH | 1 |
| Webb, HK | 1 |
| Chang, BD | 1 |
| Chen, Y | 1 |
| Diegelman, P | 1 |
| Alm, K | 1 |
| Black, AR | 1 |
| Roninson, IB | 1 |
| Croghan, MK | 3 |
| Aickin, MG | 1 |
| Meyskens, FL | 6 |
| Creagan, ET | 2 |
| Long, HJ | 1 |
| Ahmann, DL | 2 |
| Schaid, DJ | 2 |
| Harari, PM | 1 |
| Carper, SW | 1 |
| Shimm, DS | 1 |
| Frytak, S | 1 |
| Endo, Y | 1 |
| Matsushima, K | 1 |
| Onozaki, K | 1 |
| Oppenheim, JJ | 1 |
| Bregman, MD | 2 |
| Bowlin, TL | 2 |
| McKown, BJ | 1 |
| Davis, GF | 1 |
| Khomenko, AK | 1 |
| Semeniĭ, VIa | 1 |
| Gridina, NIa | 1 |
| Diachok, FI | 1 |
| Kudriavets, IuI | 1 |
| Talpaz, M | 1 |
| Plager, C | 1 |
| Quesada, J | 1 |
| Benjamin, R | 1 |
| Kantarjian, H | 1 |
| Gutterman, J | 1 |
| Kubota, S | 1 |
| Ohsawa, N | 1 |
| Takaku, F | 1 |
| Kingsley, EM | 1 |
| Glattke, T | 1 |
| Loescher, L | 1 |
| Booth, A | 2 |
| Niederkorn, JY | 1 |
| Sanborn, GE | 1 |
| Gamel, JW | 1 |
| Buckmeier, J | 1 |
| Funk, C | 1 |
| Sinervirta, R | 1 |
| Chang, CC | 1 |
| Wolf, LM | 1 |
| Leitzel, KE | 1 |
| Pegg, AE | 1 |
| Harvey, HA | 1 |
| Lipton, A | 1 |
3 reviews available for eflornithine and Malignant Melanoma
| Article | Year |
|---|---|
Chemotherapeutic implications of polyamine biosynthesis inhibition.
Topics: Animals; Drug Evaluation; Eflornithine; Female; Humans; Male; Melanoma; Mice; Middle Aged; Ornithine | 1984 |
The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening.
Topics: Animals; Anticarcinogenic Agents; Dysplastic Nevus Syndrome; Eflornithine; Fluorouracil; Humans; Mas | 1993 |
The state-of-the-art in chemoprevention of skin cancer.
Topics: Animals; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Eflornithine; Humans; Melano | 2000 |
1 trial available for eflornithine and Malignant Melanoma
| Article | Year |
|---|---|
Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Drug Evaluation; Eflornithine; Fe | 1990 |
29 other studies available for eflornithine and Malignant Melanoma
| Article | Year |
|---|---|
Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Calcitriol; Chemoprevention; D | 2013 |
Tumor suppression with a combination of alpha-difluoromethyl ornithine and interferon.
Topics: Animals; Cells, Cultured; Eflornithine; Interferons; Melanoma; Mice; Neoplasms, Experimental; Ornith | 1983 |
Stimulation of melanotic expression in murine melanoma cells exposed to polyamine antimetabolites.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Division; Cell Line; Drug Synergism; Eflo | 1983 |
Potentiation of antitumor activity of alpha-difluoromethyl ornithine by the immunomodulating peptide tuftsin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Eflo | 1983 |
Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Drug Synergism; Eflornithine; Fluorenes; L | 1984 |
Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine.
Topics: Adenosylmethionine Decarboxylase; Amidines; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 1994 |
Stress induction of the spermidine/spermine N1-acetyltransferase by a post-transcriptional mechanism in mammalian cells.
Topics: Acetylation; Acetyltransferases; Animals; CHO Cells; Cricetinae; Ditiocarb; Eflornithine; Enzyme Ind | 1993 |
Regulation of spermidine/spermine N1-acetyltransferase by intracellular polyamine pools. Evidence for a functional role in polyamine homeostasis.
Topics: Acetyltransferases; Blotting, Northern; Eflornithine; Gene Expression Regulation, Enzymologic; Homeo | 1993 |
Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO.
Topics: Animals; Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Division; Eflornithine; | 2000 |
Polyamine depletion in human melanoma cells leads to G1 arrest associated with induction of p21WAF1/CIP1/SDI1, changes in the expression of p21-regulated genes, and a senescence-like phenotype.
Topics: Adenosylmethionine Decarboxylase; Biogenic Polyamines; Cell Cycle; Cell Division; Cellular Senescenc | 2001 |
Dose-related alpha-difluoromethylornithine ototoxicity.
Topics: Adolescent; Adult; Age Factors; Aged; Audiometry; Dose-Response Relationship, Drug; Drug Evaluation; | 1991 |
Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Eflornithine; Female; | 1990 |
Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy.
Topics: Acetylation; Animals; Cell Survival; Combined Modality Therapy; Cricetinae; Cricetulus; Eflornithine | 1990 |
Role of ornithine decarboxylase in the regulation of cell growth by IL-1 and tumor necrosis factor.
Topics: Animals; Cell Division; Cell Line; DNA; Eflornithine; Glioma; Growth Inhibitors; Humans; Interleukin | 1988 |
Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid.
Topics: Cell Line; Cell Survival; Dexamethasone; Drug Combinations; Drug Synergism; Eflornithine; Humans; In | 1986 |
The effect of alpha-difluoromethylornithine on natural killer cell and tumoricidal macrophage induction by interferon in vivo.
Topics: Animals; Cytotoxicity, Immunologic; Eflornithine; Interferon Type I; Killer Cells, Natural; Macropha | 1986 |
[Antiproliferative activity of difluoromethylornithine and the factors decreasing its effectiveness in malignant growth].
Topics: Animals; Antineoplastic Agents; Bacillus megaterium; Cell Division; Cells, Cultured; Dose-Response R | 1986 |
Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Eflornithine; Female; Gastrointestinal Diseases | 1986 |
Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice.
Topics: Animals; Eflornithine; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neop | 1987 |
Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo.
Topics: Animals; Eflornithine; Female; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Polyamines | 1987 |
A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Eflornithine; Female; Hearing; Humans; Male; Me | 1986 |
Suicide enzyme inhibition as a chemotherapeutic strategy for controlling metastases derived from intraocular melanomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eflornithine; Enzyme Inhibitor | 1987 |
A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.
Topics: Adult; Aged; Combined Modality Therapy; Drug Evaluation; Eflornithine; Female; Humans; Interferon Ty | 1988 |
Median effect and long term recovery analysis of biological modifier interactions with difluoromethylornithine on the proliferation of human melanoma cells.
Topics: Cell Division; Cell Line; Culture Techniques; Dexamethasone; Eflornithine; Humans; Interferon Type I | 1987 |
Effects of inhibitors of polyamine biosynthesis on the growth and melanogenesis of murine melanoma cells.
Topics: Animals; Cell Division; Cells, Cultured; Eflornithine; Guanidines; Melanins; Melanoma; Mice; Mitogua | 1985 |
Potentiation by alpha-difluoromethylornithine of the activity of 3,4-dihydroxybenzylamine, a tyrosinase-dependent melanolytic agent, against B16 melanoma.
Topics: Catechol Oxidase; Cells, Cultured; Dopamine; Drug Synergism; Eflornithine; Humans; Melanoma; Monophe | 1985 |
Effect of inhibition of polyamine biosynthesis by DL-alpha-difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo.
Topics: Animals; Cell Division; Cells, Cultured; Eflornithine; Male; Melanins; Melanoma; Mice; Mice, Inbred | 1985 |
The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line; Cell Survival; Drug Interactions; | 1985 |
The effect of combination treatment with alpha-difluoromethylornithine and Corynebacterium parvum on B16 melanoma growth and tumoricidal effector cell generation in vivo.
Topics: Animals; Eflornithine; Immunity, Cellular; Immunity, Innate; Immunotherapy; Killer Cells, Natural; M | 1985 |